期刊文献+

EGFR、HER2在食管鳞癌中的状态及临床意义研究 被引量:3

Study on the state and clinical significance of EGFR and HER2 in esophageal squamous cell carcinoma
暂未订购
导出
摘要 目的:探讨食管鳞癌中EGFR信号传导通路相关分子EGFR、HER2的表达情况及二者之间的相互关系,对比研究免疫组织化学方法(IHC)检测食管鳞癌HER2蛋白表达和荧光原位杂交技术(FISH)检测HER2基因状态的一致性。方法:随机选取食管鳞癌根治术后的切除标本76例和21例癌旁正常鳞状上皮组织,应用IHC法检测EGFR的表达。IHC法及FISH法分别检测HER2蛋白表达和HER2基因状态,并进行对比分析。结果:EGFR在食管鳞癌的表达明显高于癌旁正常鳞状上皮(63.2%vs 33.3%,P<0.05);HER2在食管鳞癌低表达(3.9%),正常鳞状上皮不表达。EGFR、HER2表达均与脉管累犯、淋巴结转移正相关,此外,HER2表达还与肿瘤浸润深度正相关。HER2与EGFR表达未发现相关性;HER2蛋白为阳性的患者中,HER2基因扩增符合率为66.7%(2/3)。HER2蛋白为阴性的患者中,HER2基因非扩增符合率为100%(73/73)。两种方法检测结果比较差异无统计学意义(P>0.05)。结论:EGFR在食管鳞癌中高表达可能与食管鳞癌的发生发展有关,并有可能成为靶向治疗的靶点,而HER2在食管鳞癌中由于表达很低,有可能不是该肿瘤分子治疗的靶点。IHC检测HER2蛋白与FISH检测HER2基因结果一致性较高。 Objective :To explore the expressions of EGFR and HER2 in esophageal squamous cell carcinoma( ES- CC) and their relationships with clinicopathological parameters. To investigate the conformity between the HER2 pro- tein examined by immunohistochemistry (IHC) and the HER2 gene detected with fluorescence insitu hybridization (FISH). Methods:The expression of EGFR was examined by IHC in 76 surgically obtained ESCC specimens (group ESCC) and in 21 specimens of tumor - adjacent normal squamous epithelium as the controls( group C). IHC and FISH were used to detect the expression of HER2 protein and amplification of HER2 gene, respectively. Results:The ex- pressions of EGFR (63.2%) , was higher in group ESCC than those in group C ( 33.3 % , P 〈 0.05 ). In group ESCC, HER2 expression was lower in group ESCC(3.9% ) and no expression in group C. EGFR and HER2 were correlated to vascular recidivism, lymph node metastasis. Besids, HER2 was correlated to invasion of ESCC cells. No relationship was found between HER2 and EGFR. In patients whose HER2 proteins were positive, HER2 gene amplification was found,resulted in a coincidence of 66.7% (2/3). In whose HER2 proteins were negative, HER2 gene non -amplifi- cation was found, resulted in a coincidence of 100% (73/73). There was no significant difference between the two methods(P 〉0.05). Conclusion:The high expression of EGFR may correlate to tumor genesis and development of e- sophageal carcinoma and may be a new target for targeted therapy of esophageal carcinoma. The expression of HER2was low,and probably be not the target of esophageal carcinoma. There was a high coincidence between the HER2 gene examined by FISH and the HER2 protein detected with IHC.
出处 《现代肿瘤医学》 CAS 2014年第4期819-822,共4页 Journal of Modern Oncology
基金 江苏省"333"工程科研资助项目[编号:苏人才办(2009)24号]
关键词 食管肿瘤 EGFR HER2 免疫组化 荧光原位杂交 ESCC EGFR HER2 IHC FISH
  • 相关文献

参考文献18

  • 1Mariette C,Finzi L,Fabre S,et al.Factors predictive of complete resection of operable esophageal cancer:a prospective study[J].Ann Thorac Surg,2003,75 (6):1720-1726.
  • 2Boone J,Van Hillegersberg R,Offerhaus GJ,et al.Targets for molecular therapy in esophageal cell carcinoma:an immunohistochemical analysis[J].Dis Esophagus,2009,22(6):496-504.
  • 3Wolff AC,Hammond ME,Schwartz JN,et al.American Society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25 (1):118-145.
  • 4乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840. 被引量:194
  • 5王朝阳,谢宗涛.EGFR、Raf、Akt在食管鳞癌中的表达及其临床意义[J].现代肿瘤医学,2008,16(5):742-744. 被引量:4
  • 6Gibault L,Metges JP,Conan-Charlet V,et al.Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer[J].Br J Cancer,2005,93 (1):107-115.
  • 7Hanawa M,Suzuki S,Dobashi Y,et al.EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus[J].Int J Cancer,2006,118(5):1173-1180.
  • 8刘扬,庞达.FISH技术在乳腺癌HER-2基因检测中的应用[J].国际免疫学杂志,2009,32(2):110-113. 被引量:6
  • 9Agus DB,Bunn PA JR,Franklin W,et al.HER-2/neu as a therapeutic target in non-small cell lung cancer,prostate cancer,and ovarian cancer[J].Semin Oncol,2000,27 (6):53-63.
  • 10邓勇军,李海滨,沈剑,杨鸿生,洪志鹏,李定彪.食管鳞癌中人表皮生长因子受体Her-2/neu蛋白的过表达及预后意义[J].中国现代医学杂志,2009,19(24):3726-3730. 被引量:10

二级参考文献50

  • 1谭玉梅,范立青,卢光琇.表皮生长因子受体(EGFR)的细胞内信号传导[J].生命科学研究,2002,6(S1):29-33. 被引量:11
  • 2刘昭前,李慧华,周宏灏.吉非替尼治疗非小细胞肺癌的研究进展[J].中国现代医学杂志,2005,15(20):3133-3136. 被引量:5
  • 3杜长征,李惠平,侯宽永,李强,赵红梅,王墨培.中国乳腺癌妇女表皮生长因子受体-2表达的Meta分析[J].北京大学学报(医学版),2006,38(2):184-188. 被引量:16
  • 4<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:167
  • 5Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J,2006,12( Suppl 1 ) :70-80.
  • 6Nabholtz JM, Reese DM, Lindsay MA, et al. HER2-positive breast cancer:update on breast cancer international research group trials. Clin Breast Cancer,2002,3 (2) :75-79.
  • 7De Placido S,De Laurentiis M,Carlomagno C,et al. Twenty-year resuits of the Naples GUN randomized trial : predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res, 2003,9 ( 3 ) : 1039-1046.
  • 8Lin NU, Winer EP. Brain metastases: the HER-2 paradigm. Clin Cancer Res,2007,13 ( 6 ) : 1648-1655.
  • 9Kepple J, Henry-Tillman RS, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J surg,2006,192( 1 ) :68-71.
  • 10Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor,progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast ,2008,17 (5) :523-527.

共引文献207

同被引文献28

  • 1Sheng-Lei Li,Zhi-Hua Zhao,Dong-Ling Gao,Zong-Wen Liu,Qiu-Min Zhao,Jin-Xia Yu,Kui-Sheng Chen,Yun-Han Zhang.Correlation of matrix metalloproteinase suppressor genes RECK,VEGF,and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma[J].World Journal of Gastroenterology,2007,13(45):6076-6081.
  • 2KwonJ, Yoon HJ, KimJH, et al. Cetuximab inhibits cisplatininduced activation of EGFR signaling in esophageal squamous cell carcinoma[J]. Oneol Rep, 2014, 32(3) :1188-1192.
  • 3Roskoski R. ERK1/2 MAP kinases, structure, function and regulation[J]. Pharmacal Res, 2012, 66 (2) : 105-143.
  • 4Burotto M, 'Chiou VL, LeeJM, et al. The MAPK pathway across different malignancies: A new perspective[J]. Cancer, 2014, 120 (22) :3446-3456.
  • 5Upadhya D, Ogata M, Reneker LW. MAPKI is required for establishing the pattern of cell proliferation and for cell survival during lens development[J]. Development, 2013, 140(7): 1573-1582.
  • 6Zhang v, Xing X, Zhan H, et al. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells[J].J Huazhong Univ Sci Technol Med Sci, 2011, 31(6): 773-778.
  • 7Song YD, Zhang KF, Liu D, et al. Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin[J]. Tumor BioI, 2014, 35(7) :7017-7024.
  • 8Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in firstline metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie[J]. Ann On col , 2009, 20(0): 1667-1673.
  • 9Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised , open-label phase 3 trial[J]. Lancet Oncol' 2013, 14(6) :490-499.
  • 10Richards D, Kocs DM, Spira A, et al. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric andr'or gastroesophagealJunction adenocarcinoma: results of a randomised Phase 2 study[J]. EurJ Cancer, 2013, 49 (13): 2823-2831.

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部